Clinical Trials
10
5 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1950
Active, not recruiting
2
20.0%
Completed
3
30.0%
Enrolling By Invitation
1
10.0%
Not yet recruiting
2
20.0%
Recruiting
2
20.0%
No approval data available
- The European Society of Cardiology has published its first dedicated international guidelines on cardiac rehabilitation in the European Heart Journal, presented at ESC Congress 2026. - The guidelines consolidate evidence across multiple heart conditions, recommending rehabilitation beyond heart attack and heart failure to include congenital heart disease, atrial fibrillation, and cancer patients with cardiac side effects. - Cardiac rehabilitation combines exercise training, emotional support, and personalized education delivered by multidisciplinary teams, with an individualized, shared decision-making approach. - Despite evidence of cost-effectiveness, cardiac rehabilitation remains underused due to reimbursement barriers, with digitally enhanced home-based programmes highlighted as a potential solution.
- A review in Nature Reviews Cardiology traces how nicotine damages the cardiovascular system through two independent routes, suppressing prostacyclin and eNOS while releasing endothelin-1 and blocking potassium channels. - Nicotine causes measurable, reproducible vascular damage after even a single exposure, occurring across all delivery methods including smoking, heating, vaping, and oral use. - The review establishes an evidence-graded hierarchy of harm, with combustion products highest, followed by heated products, e-cigarettes, and oral nicotine products, with abstinence the only risk-free option. - Authors call for a coherent, nicotine-based regulatory framework, noting nicotine's dependence-forming potential ranks alongside cocaine and heroin.
- The AHA, ACC, ESC, and WHF published the Second Universal Definition of Heart Failure in June 2026, updating the 2021 framework to address inconsistencies in diagnosis and classification globally. - A new universal classification system for HF causes aims to standardize data reporting from registries and clinical trials, while moving away from rigid LVEF cutoff values toward a more nuanced approach accounting for age, sex, and ethnicity. - The definition emphasizes early intervention and recognizes HF as a dynamic disease with potential for improvement, remission, and recovery, rather than a fixed diagnosis. - The updated framework will serve as the foundation for the upcoming AHA/ACC Heart Failure Guideline expected in late 2027.
- An international survey of 398 respondents from 63 countries found only 10% received cardio-oncology training during medical school and 17% during residency. - A striking 87% of respondents reported no availability of structured cardio-oncology educational programmes at their institutions. - Diagnosing cancer therapy-related cardiovascular toxicity and risk stratification were identified as key priority knowledge areas by survey participants. - The ESC Core Curriculum for Cardio-Oncology and new ESC certification aim to standardise training and address these educational gaps.
- SCIRENT announced the appointment of Prof. Dr. Wilhelm Haverkamp as Chief Medical Officer, bringing over three decades of expertise in cardiac electrophysiology and drug safety to strengthen the company's clinical oversight capabilities. - Prof. Haverkamp will focus on expanding structured safety services, including establishing Data Safety Monitoring Committees and Clinical Event Committees for enhanced patient safety in clinical research. - The appointment reinforces SCIRENT's strategic commitment to advancing clinical research quality through strong medical leadership, with Prof. Haverkamp's extensive experience in cardiovascular medicine and artificial intelligence-enhanced cardiac diagnostics. - With more than 420 peer-reviewed publications and extensive experience as principal investigator in clinical trials, Prof. Haverkamp brings internationally recognized expertise in arrhythmias, heart failure, and cardiogenetics to the cardiovascular research organization.
- Recent randomized controlled trials present conflicting evidence on left bundle branch area pacing (LBBAP) versus traditional biventricular pacing for cardiac resynchronization therapy, with operator experience emerging as a critical factor. - The LECART trial demonstrated superior outcomes with LBBAP, primarily driven by reduced device-related complications requiring surgical reintervention, while the LEFT-BUNDLE-CRT trial failed to establish noninferiority. - Extended follow-up data from multiple studies suggest that while conduction-system pacing shows promise, biventricular pacing remains the established first-line therapy with the strongest evidence base. - Expert consensus indicates the field is moving toward individualized CRT approaches based on anatomy, conduction patterns, and operator expertise rather than universal replacement of conventional therapy.
- The PARACHUTE-HF trial demonstrated that sacubitril/valsartan was superior to enalapril in treating heart failure caused by Chagas disease, with a 52% higher likelihood of better primary outcomes. - The superiority was primarily driven by a significant 32% reduction in NT-proBNP levels at 12 weeks in patients receiving sacubitril/valsartan compared to enalapril. - This represents the first randomized controlled trial providing evidence for pharmacological treatment specifically in Chagas cardiomyopathy patients, a neglected disease affecting over 7 million people globally. - The international collaboration across 80+ sites in Latin America establishes a successful model for evaluating new therapies in patients with rare cardiovascular conditions.
- The DUAL-ACS trial found that 3 months of dual antiplatelet therapy (DAPT) showed signals for improved survival and lower bleeding risk compared to the standard 12-month duration in real-world heart attack patients. - The TARGET-FIRST trial demonstrated that P2Y12 inhibitor monotherapy after just one month of DAPT was noninferior to continued DAPT for cardiovascular outcomes while significantly reducing bleeding risk in low-risk patients. - Both studies challenge current ESC Guidelines recommending 12 months of DAPT after myocardial infarction, suggesting shorter treatment durations may be safer without compromising efficacy. - These findings could inform future guideline revisions for antiplatelet therapy management in post-MI patients, particularly those at low ischemic risk.
- A world-first randomized controlled trial involving 76 patients found that 12 weeks of cognitive behavioral therapy or exercise programs significantly improved heart function in patients with takotsubo syndrome. - Both interventions increased the heart's energy production and patients' exercise capacity, with walking distances improving from 402 to 458 meters in the CBT group and to 528 meters in the exercise group. - The breakthrough research, presented at the European Society of Cardiology Congress, offers hope for treating a condition that affects 5,000 Britons annually and doubles the risk of early death.
- Bempedoic acid has received a Class I, Level A recommendation in the 2025 ESC/EAS Guidelines for Management of Dyslipidaemias, marking the strongest endorsement for a non-statin therapy. - The guidelines recommend bempedoic acid for patients unable to take statin therapy to lower LDL-C levels and reduce cardiovascular events, with additional consideration for high-risk patients on maximally tolerated statin therapy. - The updated European guidelines emphasize earlier, aggressive combination therapy approaches, supporting Esperion's development of oral triple combination lipid-lowering therapies in the U.S. - Esperion's CEO highlighted that this European recognition validates bempedoic acid's clinical benefit and is expected to inform upcoming U.S. cholesterol treatment guidelines.
